- A new study suggests metformin may raise levels of Lac-Phe, a molecule linked to exercise-related metabolic changes, in men with prostate cancer.
- The finding may help explain how metformin supports metabolic health during hormone therapy, especially when fatigue limits exercise.
- This was not an anti-cancer result and it does not mean metformin can replace physical activity.
Researchers at the University of Miami looked at how metformin affects a molecule called N-lactoyl-phenylalanine, or Lac-Phe.
Lac-Phe has drawn attention because levels rise after intense exercise and may be linked to appetite regulation and energy balance.
The study found that metformin increased Lac-Phe in men with prostate cancer, even when they were not exercising at the time.
That matters because hormone therapy for prostate cancer often disrupts metabolism.
Patients can gain weight, develop insulin resistance and face a higher cardiovascular burden.
At the same time, fatigue and other treatment effects can make regular exercise harder.
So the question the researchers asked was a practical one.
Could a commonly used drug activate some of the same metabolic pathways associated with exercise, even when people are less able to move?
The answer appears to be yes, at least in part.
Importantly, the study did not find that higher Lac-Phe levels were linked to better tumour response.
This is not a cancer control story.
- Metformin may lower blood sugar through the brain as well as the body
- Metformin and Alcohol: Effects of Drinking When Taking Metformin
- Metformin may reduce long COVID risk when taken early in infection
It is a metabolic support story.
That distinction matters because the benefit, if confirmed, may lie in helping patients cope better with treatment rather than directly shrinking disease.
The study also found that Lac-Phe tracked more closely with weight change than another metformin-linked molecule, GDF-15.
That suggests metformin may influence body weight through several pathways, with Lac-Phe being one of them.
The broader takeaway is sensible.
Cancer treatment affects far more than the tumour, and supporting metabolic health can be clinically meaningful even when it does not alter PSA or disease progression directly.
